Agios (AGIO) Reports Q2 2025 Earnings with Revenue Growth and Pipeline Advancement

Agios (AGIO) reported Q2 2025 earnings with net revenue of $12.5 million, showing strong year-over-year and sequential growth. The company highlighted progress in patient enrollment for PYRUKYND and noted its upcoming FDA approval for thalassemia. The results reflect continued investment in commercial and research activities.

By Motley Fool Transcribing · Motley Fool · April 21, 2026, 16:42 UTC

Tickers: $AGIO $ALNY

Topics: earnings report FDA approval pipeline advancement R&D expenses revenue growth

Read the full article at Motley Fool

More World news

Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC
Pelagos Insurance Reports Q3 2026 Earnings with Increased Gross Premiums Written Motley Fool · November 12, 2026, 18:11 UTC
Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC
NYSE Gains $500 Billion in Market Capitalization via Nine Major Listing Transfers PR Newswire · November 12, 2026, 18:05 UTC
PenFed Foundation Grants $25,000 to Northern Virginia Vietnam Veterans Foundation PR Newswire · November 12, 2026, 18:06 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC